Middle East & Africa Vaccines Market Overview, Growth, Trends, Analysis, Research Report (2025-2031)

The Middle East & Africa Vaccines Market size is expected to reach US$ 2,738.6 Million by 2031 from US$ 2,207.0 Million in 2024. The market is estimated to record a CAGR of 3.1% from 2025 to 2031.

Executive Summary and Middle East & Africa Vaccines Market Analysis:

The MEA region's vaccines market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of MEA. Of these, the United Arab Emirates has the highest share and is a major hub for vaccine manufacture and distribution. This growth is driven by heavy investment in research and development, supported by developed infrastructure and sophisticated research facilities, majorly in the UAE and Saudi Arabia. The two nations have emphasized healthcare innovation, which created a profitable climate for scientific development in immunization. South Africa, however, will be forecast to face modest growth in the vaccine market in the coming years. This is primarily due to a boost in regional vaccine manufacturing by local pharmaceutical and biotech companies. With a focus on local manufacturing, South Africa seeks to curb import reliance, promoting cheaper vaccines and expanded access. All these efforts at the continental level cumulatively drive the dynamic of the MEA vaccine market.

Middle East & Africa Vaccines Market: Strategic Insights

Middle East & Africa Vaccines Market Segmentation Analysis:

• By Type, the Middle East & Africa Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated Vaccines segment held the largest share of the market in 2024.
• By Indication, the Middle East & Africa Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment held the largest share of the market in 2024.
• By Route of Administration, the Middle East & Africa Vaccines Market is segmented into Injection, Oral, and Other. The injection segment held the largest share of the market in 2024.
• By Age Group, the Middle East & Africa Vaccines Market is segmented into Pediatric and Adult. The pediatric segment held a larger share of the market in 2024.

Middle East & Africa Vaccines Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Vaccines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East & Africa Vaccines Market Outlook

The vaccine industry is currently experiencing a transformative phase, with combination and therapeutic vaccines emerging as the most promising opportunities for manufacturers. Innovations in these vaccines not only address evolving public health challenges but also provide significant commercial and operational advantages.
Combination vaccines are formulations designed to protect against multiple diseases in a single shot. Traditionally used in pediatric care, as seen with vaccines like MMR (measles, mumps, rubella) and DTP (diphtheria, tetanus, pertussis), combination vaccines are now expanding their reach to adult and elderly populations. This is particularly relevant for respiratory illnesses such as influenza, COVID-19, and Respiratory Syncytial Virus (RSV). Combination vaccines can greatly improve immunization rates, resulting in a quicker and more extensive reduction in disease burden. They are especially important as new vaccines for diseases such as dengue, typhoid, RSV, and tuberculosis are being developed. According to Gavi, by 2030, combination vaccines will provide protection against 30 infections with fewer doses. Major pharmaceutical companies, including Moderna, Pfizer/BioNTech, Novavax, Sanofi, GSK, and AstraZeneca, are developing combination vaccines for COVID-19, influenza, and RSV. These products are anticipated to transform seasonal immunization strategies and enhance uptake among adults and elderly populations. Additionally, therapeutic vaccines are designed not to prevent diseases but to treat existing conditions, which can include chronic infections, cancers, and allergies. This approach represents a new frontier in vaccine technology, utilizing advancements in mRNA, viral vectors, and personalized medicine. For instance, cancer vaccines aim to stimulate the immune system to recognize and attack tumor cells. Additionally, some vaccines are being developed for chronic infections such as hepatitis B and HIV.

As of 2024, the US Food and Drug Administration (FDA) has approved three therapeutic vaccines: Sipuleucel-T for advanced prostate cancer, Bacillus Calmette-Guérin for high-risk, non-muscle-invasive bladder cancer, and Talimogene laherparepvec for melanoma. As research progresses, therapeutic vaccines are expected to become a significant segment within the broader vaccine market, addressing unmet medical needs and expanding the potential customer base. Several companies are currently under trial for therapeutic cancer vaccines aimed at cancers and other chronic diseases. These vaccines are designed to enhance the body's immune response against cancer cells and are often used alongside other treatment modalities.

Both combination and therapeutic vaccines align with global health priorities by improving access, reducing the disease burden, and addressing complex health challenges. Their development benefits from significant public and private investment, collaborative partnerships, and ongoing advancements in biotechnology.
Therefore, the development of combination and therapeutic vaccines presents substantial opportunities for vaccine manufacturers to grow, innovate, and create a meaningful impact. These vaccines simplify immunization, expand their applications, and address both preventive and therapeutic health needs worldwide.

Middle East & Africa Vaccines Market Country Insights

By country, the Middle East & Africa Vaccines Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa held the largest share in 2024.

South Africa is actively investing in local vaccine manufacturing, supported by government policies prioritizing preferential procurement, long-term contracts, and tax incentives for domestic producers. According to Gavi, the African Union (AU) aims to develop, produce, and supply over 60% of the continent's vaccine doses by 2040, a significant increase from the level of less than 1% in 2021. This ambitious goal will require coordinated efforts and a strategic action plan. As an initial step, the Partnerships for African Vaccine Manufacturing (PAVM) has been established under the Africa CDC. The South African government, in partnership with Gavi, UNICEF, and other organizations, has enhanced its immunization campaigns, particularly for COVID-19 and seasonal influenza. This focus is crucial, given the country's significant burden of comorbidities such as HIV and tuberculosis.

The introduction of new vaccine types, including subunit, mRNA, and viral vector vaccines, by both international and local manufacturers has expanded the vaccine options available in South Africa. Major global companies like Pfizer, BioNTech, Sanofi, and the Serum Institute of India are actively involved in the market, introducing advanced vaccines for diseases such as COVID-19, influenza, and HPV. In December 2023, the International Finance Corporation (IFC) announced a 7 million rand loan and advisory support for Biovac to improve vaccine production and pandemic preparedness in Africa. The funding supported Biovac's production of various vaccines, including HPV and cholera. Additionally, IFC will collaborate with Biovac on a new multi-vaccine production plant in Cape Town, increasing production capacity from 150 million to about 560 million doses annually. This initiative aims to enhance local capabilities for producing both traditional bacterial-based and mRNA vaccines, reducing Africa's dependency on vaccine imports.

Middle East & Africa Vaccines Market Company Profiles

Some of the key players operating in the market include Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Vaccines Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise